Báo cáo khoa học: Structural diversity of angiotensin-converting enzyme Insights from structure–activity comparisons of two Drosophila enzymes

Structural diversity of angiotensin-converting enzyme

Insights from structure–activity comparisons of two Drosophila enzymes Richard J. Bingham1, Vincent Dive2, Simon E. V. Phillips1, Alan D. Shirras3 and R. Elwyn Isaac1

1 Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of Leeds, UK 2 Departement d’Etudes et d’Ingenierie des Proteines, Commissariat a l’Energie Atomique, CE-Saclay, Gif-Sur-Yvette, France 3 Department of Biological Sciences, University of Lancaster, UK

Keywords ACE inhibitors; angiotensin-converting enzyme (ACE); Drosophila melanogaster; peptide metabolism; peptidyl-dipeptidase

Correspondence R. E. Isaac, Faculty of Biological Sciences, Miall Building, University of Leeds, Leeds LS2 9JT, UK Fax: +44 113 34 32835 Tel: +44 113 34 32903 E-mail: r.e.isaac@leeds.ac.uk

(Received 21 September 2005, revised 15 November 2005, accepted 21 November 2005)

structure of a Drosophila angiotensin-converting enzyme The crystal (ANCE) has recently been solved, revealing features important for the binding of ACE inhibitors and allowing molecular comparisons with the structure of human testicular angiotensin-converting enzyme (tACE). ACER is a second Drosophila ACE that displays both common and dis- tinctive properties. Here we report further functional differences between ANCE and ACER and have constructed a homology model of ACER to help explain these. The model predicts a lack of the Cl–-binding sites, and therefore the strong activation of ACER activity towards enkephalinamide peptides by NaCl suggests alternative sites for Cl– binding. There is a marked difference in the electrostatic charge of the substrate channel between ANCE and ACER, which may explain why the electropositive peptide, MKRSRGPSPRR, is cleaved efficiently by ANCE with a low Km, but does not bind to ACER. Bradykinin (BK) peptides are excellent ANCE substrates. Models of BK docked in the substrate channel suggest that the peptide adopts an N-terminal b-turn, permitting a tight fit of the peptide in the substrate channel. This, together with ionic interactions between the guanidino group of Arg9 of BK and the side chains of Asp360 and Glu150 in the S2¢ pocket, are possible reasons for the high-affinity binding of BK. The replacement of Asp360 with a histidine in ACER would explain the higher Km recorded for the hydrolysis of BK peptides by this enzyme. Other differences in the S2¢ site of ANCE and ACER also explain the selec- tivity of RXPA380, a selective inhibitor of human C-domain ACE, which also preferentially inhibits ACER. These structural and enzymatic studies provide insight into the molecular basis for the distinctive enzymatic fea- tures of ANCE and ACER.

bradykinin (BK) [1]. The somatic form of the enzyme is a glycosylated type I membrane protein comprising two homologous domains, generally known as the N-domain and C-domain, arranged in tandem and joined by a short connecting peptide sequence [2].

Angiotensin-converting enzyme (ACE, EC 3.4.15.1) is a zinc peptidyl-dipeptidase, which is best known for catalysing the last step in the synthesis of the vasocon- strictor angiotensin II (AII) from angiotensin I (AI) and for the metabolic inactivation of the vasodilator

doi:10.1111/j.1742-4658.2005.05069.x

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

362

Abbreviations ACE, angiotensin-converting enzyme; ANCE, Drosophila melanogaster angiotensin-converting enzyme; ACER, Drosophila melanogaster angiotensin-converting enzyme-related; BK, bradykinin; AI, angiotensin I; AII, angiotensin II; Abz, o-aminobenzoic acid; Hip-His-Leu, hippuryl- L-histidyl-L-leucine.

Each domain is catalytically active, and both are cap- able of cleaving AI and BK. The ACE gene also gives rise to a second mammalian ACE, known as either tes- tis (tACE) or germinal ACE, through the use of an in- tragenic promoter that drives expression in developing spermatocytes. It is a single-domain enzyme that is identical with the C-domain of somatic ACE, apart from a peptide insert encoded by the testis-specific exon 13 of the ACE gene [2]. ACE knockout mice dis- play renal abnormalities, low blood pressure, anaemia and male infertility, confirming the important role of this enzyme in development, blood homoeostasis and reproduction [2].

ity to each of the two domains of mammalian ACE. ANCE and ACER have distinct tissue expression pat- terns, indicating different physiological roles [21,22]. ANCE appears to have a role in embryogenesis, meta- morphosis and reproduction [20,23,24]. A function for ACER has not been established, but the protein is associated with the developing heart in embryos and in the brain and reproductive tissues of adults (A. Carhan, R.E. Isaac and A.D. Shirras, unpublished results). The two enzymes share some enzymatic prop- erties, such as peptidyl-dipeptidase activity towards hippuryl-l-histidyl-l-leucine (Hip-His-Leu), and BK, and inhibition by inhibitors of mammalian ACE [19,20,25]. However, compared with ANCE, ACER displays more restricted substrate specificity. Although both ANCE and ACER hydrolyse Hip-His-Leu, only the ANCE activity is enhanced in the presence of NaCl [20,25]. Another interesting difference between ACER and ANCE is that the ACER active site, but not that of ANCE, can accommodate an N-domain- specific inhibitor (RXP407), indicating common active- site features for ACER and the N-domain of human ACE [17].

Although N-domain and C-domain are highly similar in protein sequence and share many enzymatic proper- ties, they can be differentiated by substrate and inhib- itor preferences and by the extent to which they are activated by Cl– [3–5]. The haemoregulatory peptide, N-acetyl-Ser-Asp-Lys-Pro (AcSDKP), another in vivo substrate for mammalian ACE, is hydrolysed more effi- ciently by the N-domain, as is the internally quenched fluorogenic substrate Abz-SDK(Dnp)P [6,7]. Cl– can stimulate the activity of both ACE domains, but the C-domain active site is more sensitive to changes in Cl– concentration [3]. The level of activation, as well as the concentration of Cl– required for maximal stimula- tion, is dependent on pH and the peptide substrate. The two domains of mammalian ACE can also be distin- guished by the N-domain-selective inhibitor RXP407 [8], the C-domain-selective inhibitor RXPA380 [9], and several BK-potentiating peptides [10].

the equivalent Cl–-binding sites

A homologue of ACE, known as ACE2, has been characterized as a single-domain type I glycoprotein [11,12]. It is important for normal contractility of heart muscle [13]. The important enzymatic feature of ACE2 is that, unlike ACE, it is a carboxypeptidase, removing a single residue from the C-terminus of peptides that have either a Pro or Leu in the P1 position, e.g. angio- tensin II, apelin 13 and dynorphin A 1–13 [14]. The activity of ACE2 is greatly enhanced in the presence of NaCl [15,16]. Therefore Cl– activation is a common feature of the mammalian members of the ACE family of peptidases.

Recent descriptions of the high-resolution molecular structure of ACE–inhibitor complexes for both human tACE [26,27] and Drosophila ANCE [28] have revealed the molecular details of the active site and how ACE inhibitors bind with high affinity. These studies con- firm many of the predictions regarding the identity of the active-site residues and, in the case of tACE, iden- tify other side chains involved in the binding of Cl– at two sites (Cl1 and Cl2) positioned outside of the active site. The crystal structure of human ACE2, with and without bound inhibitor, has also recently been repor- ted [29] and has provided a structural explanation for why ACE2 is a carboxypeptidase and not a peptidyl- dipeptidase. The structure of the native ACE2 identi- fied a single Cl–-binding site that corresponded to the Cl1 site of tACE. No bound Cl– was recognized in the crystal structure of Drosophila ANCE, and it has been in proposed that ANCE are substantially different and, in the case of Cl2, may be absent [26], which may explain the weaker effect of Cl– on enzyme activity reported for this enzyme. In ACE2, the Cl2 site also does not exist, which leaves only Cl1 as a recognized Cl–-binding site [29]. Interestingly, an alternative, but undefined, bind- ing site for Cl– has been suggested, which may be influ- ential in the conformational movement that occurs on formation of the ACE2 ES complex [26,29].

Comparative molecular and biochemical studies of members of the ACE family are likely to provide new insights into the evolution of the ACE active site, the

In vertebrates, the number of ACE genes appears to be limited to ACE and ACE2, but in some insects there has been a much greater expansion of this gene in the mosquito, Anopheles family. For example, gambiae, and in Drosophila melanogaster there are nine and six ACE genes, respectively [17,18]. Of the six Drosophila genes, only ANCE and ACER have been confirmed to produce functional metallopeptidases [19,20]. They are both single-domain proteins with (cid:1) 40% amino-acid sequence identity and 60% similar-

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

363

R. J. Bingham et al. Structure-activity of Drosophila ACEs

structural basis for differences in substrate specificity and the mechanisms by which Cl– can have profound effects on enzyme activity. In this respect, Drosophila ANCE and ACER appear to be good examples of two family members that have diverged in structure and substrate specificity and are therefore likely to provide valuable information. We now report on additional biochemical differences between ANCE and ACER the effect of Cl– on regarding substrate specificity, enzyme activity, and inhibition by new domain-select- ive inhibitors of human ACE. A model of the structure of ACER has been generated, which provides explana- tions for some of these biochemical differences.

R. J. Bingham et al. Structure-activity of Drosophila ACEs

Results

Hydrolysis of AI

(B)

The effect of NaCl on the conversion of AI into AII by ANCE was determined at two pH values. At pH 7, increasing the concentration of NaCl resulted in a faster rate of conversion, which reached a plateau at 150– 200 mm NaCl (Fig. 1A). At pH 8, maximal activity was achieved in the absence of NaCl, which had a weak inhibitory effect on the hydrolysis of AI as the salt con- centration increased from 0 to 200 mm NaCl (Fig. 1A). To further examine the effect of NaCl and pH on the mechanism of ANCE activation, the kinetic constants of AI hydrolysis were determined in the presence and absence of 100 mm NaCl at pH 7 and 8 (Table 1). The activation by NaCl at pH 7 was the result of a 330% increase in kcat ⁄ Km, which was solely attributable to a lowering of the Km. A similar rise in the kcat ⁄ Km was observed when the pH was increased from 7 to 8 in the absence of NaCl, but in this case the greater catalytic efficiency was achieved by a combined increased kcat and a lower Km. Although AI is an extremely poor sub- strate for ACER, it was possible to determine kinetic constants for this reaction (Km 1.58 ± 0.28 mm; kcat 0.01 ± 0.001 s)1), which showed that this marked dif- ference between ACER and ANCE was due to the very low kcat for AI hydrolysis by ACER. This weak pept- idyl-dipeptidase activity, unlike that of ANCE and mammalian ACE, was not stimulated by NaCl (Table 2).

Hydrolysis of enkephalin peptides

[Leu5]Enkephalin, [Met5]enkephalin and their respect- ive C-terminal amidated forms are hydrolysed at the Gly-Phe bond by both ANCE and ACER at neutral pH [20]. The endopeptidase activity of ACER, but and not ANCE,

[Leu5]enkephalinamide

towards

[Met5]enkephalinamide was stimulated in the presence of Cl– ions (Table 2). The enhancement of the hydro- lysis of the amidated peptides by 500 mm NaCl was 12-fold and 15-fold, respectively, whereas the cleavage of both [Leu5]enkephalin and [Met5]enkephalin was inhibited by (cid:1) 50% (Table 2). The NaCl-induced activ- ity of ACER was measured at different [Leu5]enkeph- alinamide and [Met5]enkephalinamide concentrations, including sub- which generated anomalous kinetics, strate concentrations above inhibition at peptide 150 lm (data not presented).

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

364

Fig. 1. (A) Effect of NaCl on the conversion of AI (200 lM) into AII by ANCE. Enzyme activity was measured using HPLC to quantify the formation of AII in Hepes buffer (h, pH 7; n, pH 8) in the pres- ence of NaCl (0–200 mM) as described in Experimental procedures. The enzyme activity is expressed as percentage of the maximum activity recorded at pH 8 in the absence of NaCl. Values are the mean of three assays and the percentage standard error of Inhibition of ANCE and ACER by the mean was 1–4%. MKRSRGPSPRR. Enzyme activity was determined using Abz- YRK(Dnp)P as described in Experimental procedures and is expressed as a percentage of the uninhibited activity.

R. J. Bingham et al. Structure-activity of Drosophila ACEs

Table 1. Effect of NaCl on the kinetic constants for the conversion of AI into AII by ANCE. Kinetic constants for the conversion of AI into AII were determined as described in Experimental procedures and are expressed as the mean ± SEM (n ¼ 3).

)1)

)1)

0 mM [NaCl] 100 mM [NaCl]

Km (mM) kcat (s)1) kcat ⁄ Km (s)1ÆlM Km (mM) kcat (s)1) kcat ⁄ Km (s)1ÆM

2.70 ± 0.67 1.23 ± 0.17 pH 7.0 pH 8.0 6.84 ± 1.04 11.06 ± 0.86 0.82 ± 0.14 1.04 ± 0.21 6.83 ± 0.46 10.78 ± 1.12 2.53 · 10)3 8.99 · 10)3 8.33 · 10)3 10.37 · 10)3

Table 2. Effect of NaCl on the hydrolysis of peptides by ACER. The rate of hydrolysis of peptides (200 lM) was determined in 0.1 M Hepes ⁄ 10 lM ZnSO4, pH 7 as described in Experimental proce- dures. Values are mean ± SEM (n ¼ 3).

Reaction rate (units ⁄ h)

in greatly increased affinity between the substrate and ANCE, but not ACER. Indeed the Km value for the hydrolysis of [Thr6]BK was so low that it was difficult to obtain accurate Km values using HPLC to quantify reaction rates at very low substrate concentrations. We therefore used [Thr6]BK as an inhibitor of the hydro- lysis of Abz-YRK(Dnp)P and obtained a Ki value of 23 ± 4 nm, confirming the very high affinity displayed by ANCE for this peptide.

0 mM NaCl 500 mM NaCl Substrate

a Units of activity, nmol AII formed per lg ACER. b Units of activity, nmol dipeptide released per lg ACER.

Hydrolysis of BK and related peptides

inhibition of ANCE (Fig. 1B).

MKRSRGPSPRR is an invertebrate BK-like peptide predicted to be a cleavage product of a neuropeptide precursor gene in Aplysia californica [30]. HPLC analy- sis showed that MKRSRGPSPRR was an excellent substrate for ANCE, but was resistant to hydrolysis by ACER. MS confirmed that reaction products were MKRSRGPSP ([M + H]+, m ⁄ z 1014.3) and MKRSRGP ([M + H]+, m ⁄ z 830.4), generated by the sequential cleavage of Arg-Arg and Ser-Pro. MKRSRGPSPRR was a strong inhibitor of the hydro- lysis of Abz-YRK(Dnp)P with a Ki of 185 nm for the In contrast, MKRSRGPSPRR, even at a concentration of 100 lm, did not significantly inhibit ACER activity, measured with the same fluorogenic substrate.

Homology model of the structure of ACER

Initial velocities for the hydrolysis of the BK peptides were obtained by determining the rate of release of the C-terminal dipeptide (Phe-Arg for BK, [Thr6]BK and Ile-Ser-BK; Tyr-Arg for [Tyr8]BK). ANCE consis- tently cleaved these peptides with much greater effi- ciency (kcat ⁄ Km) than ACER, mainly because of the lower affinity of ACER for these substrates (Table 3). In the case of ANCE, extending BK at the N-terminus with Ile-Ser had no significant effect on the Km and kcat, and replacing the Phe8 of BK with tyrosine resul- ted in a modest increase in both the Km and kcat. In contrast, replacing Ser6 of BK with threonine resulted

We generated a model of ACER based on the crys- structure of ANCE. The homology model tal

AIa [Leu5]Enkephalinb [Met5]Enkephalinb [Leu5]Enkephalinamideb [Met5]Enkephalinamideb 0.033 ± 0.002 36.9 ± 1.0 23.8 ± 0.03 10.1 ± 0.4 3.3 ± 0.1 0.025 ± 0.002 19.6 ± 1.6 9.9 ± 1.0 123.2 ± 1.8 49.3 ± 4.0

Table 3. Kinetic constants for the hydrolysis of bradykinin-related peptides by ANCE and ACER. –, No detectable hydrolysis of the peptide and no inhibition of the cleavage of Abz-YRK(Dnp)P by ACER.

)1)

ANCE ACER

Substrate kcat (s)1) kcat ⁄ Km s)1(lM))1 Km (lM) kcat (s)1) kcat ⁄ Km (s)1ÆlM Km (lM)

a Km determined from the IC50 value obtained by measuring initial rates of hydrolysis of the fluorogenic substrate Abz-YRK(Dnp)P (5 lM) in the presence of different concentrations of MKRSRGPSPRR. b Estimated from the initial velocity recorded at a substrate concentration 100 times greater than the Km.

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

365

BK (RPPGFSPFR) Ile-Ser-BK (ISRPPGFSPFR) [Tyr8]BK (RPPGFSPYR) [Thr6]BK (RPPGFTPFR) MKRSRGPSPRR 0.27 ± 0.05 0.30 ± 0.005 0.58 ± 0.08 0.073 ± 0.04 0.37a ± 0.1 1.09 ± 0.03 1.10 ± 0.005 2.41 ± 0.12 0.24 ± 0.008 18.8b ± 0.5 4.04 3.66 4.15 3.31 50.81 4.88 ± 0.97 5.54 ± 0.98 11.3 ± 3.46 5.67 ± 1.58 – 0.54 ± 0.03 0.17 ± 0.01 1.17 ± 0.11 0.60 ± 0.04 – 0.09 0.03 0.10 0.11 –

R. J. Bingham et al. Structure-activity of Drosophila ACEs

Fig. 2. Surface representations of the elec- trostatic potential of ANCE and a homology model of ACER. The proteins have been sliced in half to show the internal substrate- binding channel. The N-chamber and C-chamber (N and C) are postulated to bind up to (cid:1) 7 N-terminal residues and the C-ter- minal dipeptide of substrate, respectively. Molecular surfaces and electrostatic poten- tial were calculated with the program SPOCK (http://quorum.tamu.edu). ANCE co-ordi- nates were obtained from the recently determined crystal structure (PDB accession code 1J36). The homology model of ACER was generated in SWISS-MODEL using the ANCE structure as a template. Positive and negative charges are represented by shades of blue and red, respectively, with neutral areas coloured white.

Selective inhibitors of ANCE and ACER

Inhibition constants were determined for RXPA380, RXPA381 and RXPA384 for both ANCE and ACER (Table 5). These values showed that RXPA384 was only slightly more potent as an inhibitor of ACER,

allowed us to compare the structure of the sub- strate ⁄ inhibitor binding sites between these related enzymes, which are very similar in primary protein structure, but display quite different enzymatic prop- erties. One of the striking differences between ANCE is a significant and ACER predicted by our model change in the electrostatic charge that lines the sub- strate-binding channel, a change from predominantly negative charges in ANCE to positive charges in ACER (Fig. 2). To gain insight into why BK pep- tides bind with higher affinity to ANCE than to ACER, we docked BK and [Thr6]BK into the ANCE substrate channel. The modelling predicts that the negatively charged side chain of Asp360, as well as Glu150, forms favourable ionic interactions with the positively charged C-terminal arginine of both substrates (Fig. 3). Interestingly, in ACER, this interaction is lost because Asp360 is replaced with His368 (Table 4). The models of BK and [Thr6]BK bound to ANCE suggest that the extra methyl group of [Thr6]BK occupies a small hydrophobic pocket, which is conserved in both ANCE and ACER. The models also suggest that the two peptides bind in a similar orientation, with a b-turn centred on the resi- dues Pro2-Pro3.

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

366

Fig. 3. A stick diagram showing predicted electrostatic interactions between the C-terminal Arg9 of BK and ANCE. The interactions between Asp360 of ANCE and the guanidino group of Arg9 of BK will be lost in ACER as Asp360 is replaced with His368.

R. J. Bingham et al. Structure-activity of Drosophila ACEs

A

Table 4. Comparison of the residues that contribute to the S2¢ sub- site of human C-domain ACE (the residue numbers for human tACE are in parentheses) with the N-domain of human ACE, ANCE and ACER.

N-domain ACE C-domain ACE (tACE) ANCE ACER

B

Gln857 (281) Thr858 (282) Glu952 (376) Val955 (379) Val956 (380) Asp991 (415) Asp1029 (453) Phe1033 (457) Phe1036 (460) Lys1087 (511) Tyr1096 (520) Tyr1099 (523) Phe1103 (527) Gln265 Gln266 Asp360 Phe363 Thr364 Asp399 Asp437 Phe441 Phe444 Lys495 Tyr504 Tyr507 Phe511 Gln274 Ser275 His368 Tyr371 Val372 Asp407 Ser445 Phe449 Phe452 Lys503 Tyr512 Tyr515 His519 Gln259 Ser260 Asp354 Ser357 Thr358 Asp393 Glu431 Phe435 Phe438 Lys489 Tyr498 Tyr501 Phe505

interactions. Table 5. Potency of RXPA series of compounds as inhibitors of ANCE and ACER. ANCE and ACER activities were measured using the fluorogenic substrate Abz-YRK(Dnp)P (5 lM) as described in Experimental procedures. –, No inhibition with 100 lM RXPA380.

Ki (nM)

ANCE ACER Inhibitor

whereas RXPA381 was able to distinguish between the two enzymes with a selectivity factor of more than 100 in favour of ACER. RXPA380 inhibited ACER with a Ki of 4.8 lm, but did not inhibit ANCE, even at a con- centration of 100 lm.

– 365 152 4800 3 95 RXPA380 (Cbz-Phew[PO2-CH]Pro-Trp-OH) RXPA381 (Cbz-Phew[PO2-CH]Ala-Ala-OH) RXPA384 (Cbz-Phew[PO2-CH]Ala-Trp-OH)

the hydrophobicity of

from the inhibitor so that the change in the size of the side chain may have minimal effect on binding. Val956 of C-domain ACE is conserved in ACER as Val372, but in ANCE this is replaced by Thr364, which redu- the ANCE S1¢ pocket ces (Fig. 4A). In ANCE, Gln266 with its large polar side chain replaces Ser275 and Thr858 of ACER and C-domain ACE, respectively (Table 4). In our model, the larger side chain of Gln266 restricts the space available and results in steric hindrance of the large indole ring of RXPA380 (Fig. 4A).

To understand the molecular basis behind the select- ive inhibition of ACER by RXPA380 and RXPA381, these molecules were modelled into the binding sites of ANCE and ACER. The model of RXPA380 ⁄ ACER shows that RXPA380 is bound in a very similar orien- tation to the model generated for RXPA380 ⁄ C-domain ACE [31]. Phe1033 and Phe1103 of C-domain ACE are important in forming a hydrophobic side of the S2¢ pocket for binding the tryptophan of RXPA380. Both in these residues are conserved in ANCE, but of ACER, Phe1103 is replaced with His519 (Table 4). The other side of the S2¢ pocket is formed by two adjacent valine residues in C-domain ACE (Val955 and Val956). Val955 is replaced by larger phenylalan- ine and tyrosine residues in ANCE and ACER, respectively, which in our models are pointing away

In RXPA381, the P1¢ and P2¢ proline and trypto- phan residues of RXPA380 are replaced by smaller alanine residues. The models of RXPA381 bound to

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

367

Fig. 4. Representations of enzyme–inhibitor (A) RXPA380 bound to C-domain ACE (grey), superimposed on the crystal structure of ANCE (yellow), highlighting differences between the proteins at the S2¢ pocket. The absence of inhibition of ANCE by RXPA380 can be explained by the replacement of Thr858 with the larger Gln266, and Val956 with the polar Thr364. The combined effects of these changes will be to reduce the hydrophobic nature of the S2¢ site and restrict the space available for the large indole ring of RXPA380. In ACER, the equivalent of Thr858 of C-domain ACE is the smaller Ser275, whereas Val956 is conserved as Val372. This is consistent with the inhibition of ACER by RXPA380. (B) Space-filling representation of RXPA381 bound to ANCE (left) and ACER (right) in the S2¢ pocket, comparing the differences in packing of the P2¢ methyl group of RXPA381 (arrowhead) against Val372 of ACER or the equivalent Thr364 in ANCE. The tyrosine and lysine residues interacting with the C-terminus of the inhibitor are labelled. The figure was generated in PYMOL.

the methyl groups of

ANCE and ACER show that the inhibitor is bound in a similar orientation, but with variation in the orienta- tion of the C-terminal residue (Fig. 4B). All S1¢ and S2¢ residues interacting directly with RXPA381 are con- for the served between ANCE and ACER except aforementioned Val372 (ACER) and Thr364 (ANCE) (Table 5). The molecular dynamic simulations suggest that the two alanines of RXPA381 pack closely with Val372 of ACER, whereas in ANCE, the methyl group of the terminal alanine residue is orientated away from Thr364, reinforcing the importance of the hydrophobicity of the valine side chain.

R. J. Bingham et al. Structure-activity of Drosophila ACEs

Discussion

Trp485 and Arg489. Whereas Arg489 is conserved, Arg186 and Trp485 of tACE are replaced by Tyr170 and Phe469 in ANCE. It has been proposed that the Arg fi Tyr substitution may result in a Cl–-binding site more similar to the ACE Cl2 binding site [26]. Although the Trp fi Phe substitution is expected to reduce the affinity for Cl–, it is possible that the Cl1 site in ANCE may still bind the anion and that this interaction is responsible for our observed increase in affinity of ANCE for AI. In ANCE, the potential Cl1 binding site is adjacent to the peptide backbone of Lys495, which our modelling, together with recent site- directed mutagenesis studies on human ACE [33], suggest direct interactions between Lys495 and the C-terminus of the peptide substrate (Fig. 3). The pres- ence of a Cl– ion at this site may have a stabilizing effect on binding certain substrates.

We have characterized the effect of Cl– on ANCE activity by determining the kinetic constants for the hydrolysis of AI in the absence and presence of NaCl (100 mm). The increased kcat ⁄ Km observed at pH 7, was entirely the result of a 3.5-fold lowering of the Km for AI. A similar level of enhancement was also achieved in the absence of NaCl by changing the pH conditions from 7 to 8, although in this case changes in both the Km and kcat contributed to the increased catalytic efficiency. Although these effects are signifi- cant, they are modest compared with the activation by NaCl of the AI-converting activities of the C-domain of human ACE [3,32]. ACER hydrolyses AI extremely slowly, an activity that is not stimulated by Cl–. Never- theless, a strong effect of NaCl on the peptidase activity of ACER was observed when either [Leu5] enkephalinamide or [Met5]enkephalinamide was the substrate.

In the N-domain of human ACE, and in ACER, the Cl1 site is altered by the replacement of Arg186 of tACE with His164 and His177, respectively, making it unlikely that Cl– will bind at this position in both these enzymes [26]. However, there is a possibility that an alternative Cl–-binding site exists in the N-domain of human sACE, as the R500Q mutant of the human ACE N-domain, which removes the Cl2 site, responds to 20 mm NaCl by a twofold increase in affinity for AI [32]. The strong NaCl-induced activation of ACER activity towards the amidated enkephalin substrates and the unlikely involvement of the Cl1 and Cl2 sites in this effect suggest that a different anion site may also be present in ACER. A similar proposal for a Cl–-binding site, distinct from the two identified in tACE, has been put forward to explain the Cl–-enhanced carboxypeptidase activity of human ACE2 [29]. The lack of understanding of the molecu- lar mechanism by which Cl– influences the catalytic activity of ACEs is illustrated by the recent characteri- zation of ACE from the leech Theromyzon tessulatum [34]. The residues forming both Cl1 and Cl2 in tACE are absolutely conserved in the leech enzyme, suggest- ing that this ACE would, like human C-domain, be strongly activated by NaCl. However, the enzyme when expressed in mammalian cells responds with only modest activation (twofold) of the hydrolysis of Hip- His-Leu by NaCl with an optimal Cl– concentration of 50 mm, and, thus, resembles the N-domain rather than the C-domain of human ACE.

the more

Our observation that NaCl alters the affinity of ANCE for AI suggests that the binding of Cl– induces a conformational change in ANCE that influences the hydrolysis of AI. The molecular structures of two Cl–- binding sites (Cl1 and Cl2) are known from the struc- ture of human tACE [27], but no Cl– anions were identified in the crystal structure of ANCE [28]. The Cl2 Cl–-binding site of tACE, 10 A˚ from the catalytic zinc, is closer to the active site than Cl1 and comprises the side chains of Arg522, Trp220 and Tyr224. Com- paring the structures of ANCE, ACER and tACE at the Cl2 binding site suggests that ANCE and ACER would not bind Cl– at the Cl2 site. The substitution of Pro519 in tACE by a glutamate in both ANCE and ACER results in the carboxylic acid of this residue residing in the space occupied by Cl– in the tACE crys- tal structure [26].

The Cl1 binding site of tACE lies 20 A˚

All the BK peptides used in this study were cleaved by both ANCE and ACER, although ANCE was invariably enzyme, displaying efficient kcat ⁄ Km values 30–100-fold greater than those obtained with ACER. Our model of ANCE with either BK or [Thr6]BK docked in the substrate channel suggests

from the catalytic zinc and involves three contacts, Arg186,

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

368

the substitution of

the acidic side chains of Asp360, as well as that Glu150, form favourable ionic interactions with the positively charged C-terminal Arg of the peptides. These residues are conserved in the human N-domain and C-domain active sites (Table 5), both of which efficiently cleave BK. However, Asp360 of ANCE is replaced with His368 in ACER, and this change in the electrostatic charge in the S2¢ pocket is predicted to reduce ionic interactions between ACER and the guanidino group of the C-terminal arginine of the BK peptides. This may explain why the Km values for the hydrolysis of BK, Ile-Ser-BK, [Thr6]BK and [Tyr8]BK by ACER are 20–75-fold higher than the correspond- ing values for ANCE. The model also suggests that an N-terminal b-turn centred on the residues Pro2-Pro3 of BK and [Thr6]BK allows the peptides to fit tightly into the larger (N chambers) of the two active-site cav- ities, which may explain why BK peptides bind with much higher affinity to ANCE and ACER than AI. BK adopts a similar conformation in models of BK bound to human C-domain ACE (R. J. Bingham, unpublished work), which would provide an explan- ation for why BK is the physiological substrate that displays the highest-affinity of any substrate of the human enzyme [2].

The affinity of BK for ANCE is increased almost fourfold by introducing an extra methyl group in [Thr6]BK. It has been shown previously that [Thr6]BK has a markedly different solution structure to BK [35] and has a greater tendency to adopt an N-terminal b-turn, which was also a consistent feature of our molecular modelling. The dynamic structure difference between BK and [Thr6]BK provides a possible explan- ation for the difference in binding affinity of these two BK peptides to ANCE.

substrates,

charged

peptide

MKRSRGPSPRR is structurally related to mamma- lian BKs and was shown to be an excellent ANCE substrate. In contrast, this peptide was resistant to hydrolysis by ACER and did not compete with sub- strate for the enzyme active site. The surface of the ACER active site is predicted to be positively charged, which would present an unfavourable electrostatic environment for Arg ⁄ Lys-rich peptides attempting to access the substrate-binding channel. In contrast, the negative charges lining the ANCE substrate chan- nel would be expected to favour interactions with especially positively MKRSRGPSPRR, which has positive charges along the length of the peptide.

RXPA380 (Cbz-Phew[PO2-CH]Pro-Trp-OH)

important for determining this selectivity [31]. For both ANCE and ACER, it is clear that proline in the P1¢ position does not allow strong inhibitor–enzyme inter- the P1¢ proline of action, as RXPA380 with alanine in RXPA384 (Cbz-Phew[PO2- CH]Ala-Trp-OH) makes a much more potent inhibitor of both ANCE and ACER. The proline in RXPA380 probably restricts the orientation of the P2¢ side chain to an orientation that is less favourable for interactions in the S2¢ pocket of ANCE. Of the 12 residues of the S2¢ subsite of C-domain ACE that are predicted to interact with the RXPA380 in a model of the inhibitor–enzyme complex [31], only eight are strictly conserved in the N- domain, nine in ANCE and eight in ACER (Table 4). The adjacent valines (Val955 and Val956) that help form the S2¢ pocket of C-domain ACE appear to be involved in binding the tryptophan side chain of RXPA380. It has been proposed that replacement of these two residues in N-domain ACE with polar serine and threonine will limit favourable hydrophobic inter- actions between inhibitor and enzyme [31]. RXPA380 inhibits ACER, albeit weakly, but not ANCE. Our model of the ACER–RXPA380 complex shows the inhibitor bound in a very similar orientation to that des- cribed for C-domain ACE, with the side chain of to Val956 of C-domain ACE) Val372 (equivalent involved in ligand interaction at the S2¢ pocket. The replacement of Val372 of ACER with the polar Thr364 in ANCE probably contributes towards the lack of inhibitory activity of RXPA380. This supports the hypothesis that the hydrophobicity of Val956 in C- domain ACE and Val372 in ACER is important for RXPA380 selectivity. In our model, the larger side chain of Gln266 restricts the space available for the large in- dole ring of RXPA380 and would therefore contribute together with Thr364 towards hindrance of RXPA380 binding to ANCE. In contrast, Thr858 of C-domain ACE is replaced by the smaller Ser275, and ACE Val956 is conserved as Val372 in ACER, which is con- sistent with the inhibition of ACER by RXPA380. RXPA381, which has alanine in both the P1¢ and P2¢ positions, inhibits both ANCE and ACER, but displays 100-fold selectivity in favour of ACER. This selecti- vity is consistent with the observation that RXP407 (Ac-Asp-Phew[PO2-CH]Ala-Ala-NH2) and Ac-Asp- Phew[PO2-CH]Ala-Ala-OH with a P1¢ and a P2¢ alanine are also selective inhibitors of ACER [17]. The side chain of Gln266 of ANCE, which forms the back of the S2¢ site, is too distal (8 A˚ ) to interact with the P2¢ side chains of RXPA381 and RXP407, and therefore will not influence the binding of these less bulky inhibitors.

The unexpected result that ACER is inhibited by both an N-domain-selective and a C-domain-selective

is a highly selective inhibitor of the C-domain of somatic ACE, with the pseudo-proline and the tryptophan resi- dues in the P1¢ and P2¢ positions of the inhibitor being

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

369

R. J. Bingham et al. Structure-activity of Drosophila ACEs

determined by absorbance at 280 nm. Cl–-free protein was produced by dialysing 1 mL protein solution (1 mgÆmL)1) against 5 L MilliQ water for 24 h followed by dialysis against 100 mm Hepes (pH 8.0) ⁄ 10 lm ZnSO4 for 24 h.

Enzyme assays

inhibitor demonstrates the dangers of classifying ACEs as either N-domain-like or C-domain-like. Molecular models of inhibitors complexed with ANCE and ACER have suggested structural explanations for these obser- vations and provided new insights into how structural diversity in the ACE substrate channel can lead to important differences in enzymatic properties. In addi- tion, our models of BK docked at the ACE active site have provided an explanation for the evolutionarily conserved tight binding of this substrate to ACE.

R. J. Bingham et al. Structure-activity of Drosophila ACEs

Experimental procedures

Enzyme substrates and inhibitors

Peptides were purchased from Sigma-Aldrich (Poole, Dorset, UK). RXPA380 (Cbz-Phew[PO2-CH]Pro-Trp-OH), (Cbz-Phew[PO2-CH]Ala-Ala-OH), RXPA384 RXPA381 (Cbz-Phew[PO2-CH]Ala-Ala-OH) were synthesized as des- cribed previously [8,31]. Abz-YRK(Dnp)P was a gift from Professor Adriana K. Carmona, Department of Bio- physics, Division of Nephrology, Escola Paulista de Medici- na, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.

Expression and purification of recombinant ANCE and ACER

Dipeptidyl carboxypeptidase activity towards peptide sub- strates was determined by HPLC quantification (214 nm) of the reaction products (AII for the hydrolysis of AI; Phe-Arg for the hydrolysis of BK, Ile-Ser-BK and [Thr6]BK; Tyr- Arg for the hydrolysis of [Tyr8]BK; MKRSRGPSP for the hydrolysis of MKRSRGPSPRR; Tyr-Gly-Gly, Phe-Leu- amide and Met-Leu-amide for [Leu5]enkephalinamide and [Met5]enkephalinamide; Tyr-Gly-Gly, Phe-Leu and Met- Leu for [Leu5]enkephalin and [Met5]enkephalin). Unless otherwise stated, the reactions were carried out at 35 (cid:1)C in 100 mm Hepes (pH 8.0) ⁄ 50 mm NaCl ⁄ 10 lm ZnSO4 in a final volume of 20 lL for AI and larger volumes (200 lL to 1 mL) for BK and BK-related peptides. Reactions were stopped by either addition of trifluoroacetic acid to a final concentration of 2.5% or, for larger volumes, immersion in boiling water for 5 min. HPLC analysis required different reverse-phase columns and elution conditions to achieve peptide separation. The products of AI, MKRSRGPSPRR, and BK hydrolysis were resolved using a Phenomenex Jupiter C18 (5 lm particles, 250 · 4.6 mm; Phenomenex, Macclesfield, Cheshire, UK) column, whereas the separation of BK 1–5 and BK 1–7 required a SuperPac Pep-S column (5 lm particles, 250 mm · 4 mm; Amersham Biosciences). The following elution gradients of acetonitrile in 0.1% tri- fluoroacetic acid at a flow rate of 1 mLÆmin)1 were used: 15–36% acetonitrile over 14 min for AII; 6–24% acetonitrile over 22 min for Phe-Arg and MKRSRGPSP; 6–18% aceto- nitrile for BK 1–5 and BK 1–7 over 20 min; 0–24% acetonit- rile over 20 min for the separation of Tyr-Gly-Gly, Phe-Leu, Met-Leu, Phe-Leu-amide and Met-Leu-amide. Identification of peptides by MS was performed using a Q-Tof MS ⁄ MS instrument. Hip-His-Leu hydrolysis was assayed as des- cribed previously [36].

substrate

the

The kinetics of inhibition of ANCE and ACER by BK, BK-related peptides and phosphinic acid inhibitors were determined by measuring the effects on initial rates of hydrolysis of Abz-YRK(Dnp)P (5 lm) in 100 mm Hepes, pH 8.0, 50 mm NaCl and 10 lm ZnSO4 (final reaction vol- ume, 100 lL). ANCE and ACER hydrolysed Abz- YRK(Dnp)P, a fluorogenic substrate based on the structure of N-acetylSDKP [7], with Km values of 6.64 ± 1.1 lm and 4.60 ± 1.4 lm, respectively. The reactions were performed at 20 (cid:1)C in 96-well black plastic plates (Corning Life Sciences, High Wycombe, Buckinghamshire, UK) using a Victor2 fluorimeter (PerkinElmerTM, Turku, Finland) to quantify the rate of increase in fluorescence (kem 430 nm and kex 340 nm). The reaction was started by adding the

Recombinant ANCE and ACER were produced by expres- sion in Pichia pastoris, as described previously [20,25]. Secre- ted ANCE and ACER were purified to homogeneity from the culture medium by using a combination of hydrophobic interaction and ion-exchange chromatography. (NH4)2SO4 was added to the culture media to a final concentration of 1.5 m, and, after centrifugation and filtration (0.2 lm pore size; Minisart, Sartorius Ltd, Epsom, Surrey, UK), the cul- ture media were applied to a column (12 cm · 2.6 cm) packed with Phenyl-Sepharose Fast Flow 6 (Amersham Biosciences, Chalfont St Giles, Buckinghamshire, UK) pre-equilibrated with 1.5 m (NH4)2SO4 ⁄ 20 mm Tris ⁄ HCl, pH 8.0. Protein was eluted with a decreasing gradient of (NH4)2SO4 (1.5–0 m; over 500 mL; flow rate of 5 mLÆmin)1) and monitored using a UV detector set at 280 nm. Protein- containing fractions were pooled and dialysed against 20 mm Tris ⁄ HCl, pH 8.0, before being applied to an ion- exchange column (HiTrap Q HP, 5 mL bed volume; Amer- sham Biosciences). Protein was eluted using a 200 mL gradi- ent of increasing concentration of NaCl (0–1 m), at a flow rate of 5 mLÆmin)1. Fractions containing enzyme activity, determined using Hip-His-Leu as [36], were pooled and dialysed against 100 mm Tris ⁄ HCl (pH 7.0) ⁄ 50 mm NaCl ⁄ 10 lm ZnCl2, before being concen- trated to 1 mg protein per ml of buffer using a centrifugal concentrator (Microsep 10k; Pall Life Sciences, Portsmouth, Hampshire, UK). The final protein concentration was

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

370

enzyme

to

100 mm Tris ⁄ HCl

the substrate in (pH 7.0) ⁄ 100 mm NaCl ⁄ 10 lm ZnCl2.

Kinetic parameters and IC50 values were calculated using nonlinear regression curve-fitting programs (figp; Biosoft, Cambridge, UK). Error values are standard deviations of the parameters calculated from the fitted curve by figp. The Ki of inhibition of ANCE by [Thr6]BK was determined by measuring the kinetics of Abz-YRK(Dnp)P hydrolysis in the presence of 0, 10, 20, 50 and 80 nm [Thr6]BK.

(University of Leeds) for technical expertise, Alison Ashcroft (University of Leeds) for mass spectrometry, Philippe Cuniasse (Commissariat a l’Energie Atomi- que, CE-Saclay) for the pdb file of RXPA380, and Pierre Corvol, Tracy Williams and Xavier Houard (College de France, Paris) for Pichia expressing ANCE and ACER. We acknowledge the support of the Bio- technology and Biological Sciences Research Council through a studentship to R.J.B. and a grant to A.D.S. and R.E.I. (No. 89 ⁄ S19378).

Molecular modelling

R. J. Bingham et al. Structure-activity of Drosophila ACEs

References

1 Erdos EG (1990) Angiotensin-I converting enzyme and the changes in our concepts through the years. Hyper- tension 16, 363–370.

2 Corvol P, Eyries M & Soubrier F (2004) Peptidyl-dipep- tidase A ⁄ angiotensin I-converting enzyme. Handbook of Proteolytic Enzymes (Barrett, AJ, Rawlings, ND & Woessner, JF, eds), pp. 332–346. Elsevier ⁄ Academic Press, Amsterdam.

3 Wei L, Alhencgelas F, Corvol P & Clauser E (1991) The 2 homologous domains of human angiotensin-I- converting enzyme are both catalytically active. J Biol Chem 266, 9002–9008.

4 Wei L, Clauser E, Alhencgelas F & Corvol P (1992) The 2 homologous domains of human angiotensin-I- converting enzyme interact differently with competitive inhibitors. J Biol Chem 267, 13398–13405.

5 Jaspard E, Wei L & Alhenc-Gelas F (1993) Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 268, 9496–9503.

6 Rousseau A, Michaud AM-TC, Lenfant M & Corvol P (1995) The hemoregulatory peptide N-acetyl-Ser-Asp- Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem 270, 3656–3661.

7 Araujo MC, Melo RL, Cesari MH, Juliano MA,

Juliano L & Carmona AK (2000) Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme. Biochemistry 39, 8519–8525.

The model of D. melanogaster ACER was generated in swiss-model [37] using the first approach mode and the crys- tal structure of ANCE as a template (Protein DataBank accession code 1J36). The zinc atom was manually posi- tioned, co-ordinated by His375, Glu376 and His379, which were deduced to be the co-ordinating residues by sequence alignment. The co-ordinates of BK and [Thr6]BK were gen- erated in pymol (http://www.pymol.org), and manually posi- tioned into the binding channel of ANCE and ACER using the molecular visualization program O. The peptide was aligned such that the carboxy group of the scissile peptide bond was orientated towards the zinc according to the pro- posed catalytic mechanism [27]. The large N-chamber and C-chamber readily allowed positioning of the peptide with minimal steric clashes. The model was then solvated with explicit water molecules in a 20 A˚ sphere centred on the pep- tide. This model was improved by energy minimization and molecular-dynamics simulations using the ds Modelling soft- ware (Accelrys, San Diego, CA, USA). All energy calcula- tions were performed using the CHARM22 force field, and were restricted to the 20 A˚ sphere centred on the peptide. The nonbonded cut-off was set to 12 A˚ . Initial optimization was performed by two stages of energy minimization, firstly 500 steps of a conjugate gradient minimization, followed by 1000 steps using the adopted basis Newton–Raphson algo- rithm. This was followed by heating to and equilibrium at 300 K before a 1000-step molecular-dynamics simulation with time steps of 0.001 ps. Co-ordinates of RXPA380 were kindly provided by Philippe Cuniasse, Departement d’Etudes et d’Ingenierie des Proteines, Commissariat a l’Energie Atomique, CE-Saclay, Gif-Sur-Yvette, France. Co-ordinates of RXPA381 were generated in pymol. These co-ordinates were then superimposed on to ANCE and ACER assuming a similar binding orientation to ACE C-domain. This model was then solvated with explicit water molecules in a 20 A˚ sphere centred on the peptide and then subjected to the molecular modelling scheme described above.

8 Dive V, Cotton J, Yiotakis A, Michaud A, Vassiliou S, Jiracek J, Vazeux G, Chauvet MT, Cuniasse P & Corvol P (1999) RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to dif- ferentiate between its two active sites. Proc Natl Acad Sci USA 96, 4330–4335.

9 Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A

Acknowledgements

& Dive V (2003) Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage

We thank Adriana K. Carmona (Universidade Federal de Sao Paulo) for ACE substrates and Pam Gaunt

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

371

of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res 93, 148–154.

21 Tatei K, Cai H, Ip YT & Levine M (1995) Race: a Drosophila homolog of the angiotensin-converting enzyme. Mech Dev 51, 157–168.

22 Taylor CAM, Coates D & Shirras AD (1996) The Acer gene of Drosophila codes for an angiotensin-converting enzyme homolog. Gene 181, 191–197.

23 Siviter RJ, Taylor CA, Cottam DM, Denton A, Dani

10 Cotton J, Hayashi MA, Cuniasse P, Vazeux G, Ianzer D, De Camargo AC & Dive V (2002) Selective inhibi- tion of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides. Biochemis- try 41, 6065–6071.

MP, Milner MJ, Shirras AD & Isaac RE (2002) Ance, a Drosophila angiotensin-converting enzyme homologue, is expressed in imaginal cells during metamorphosis and is regulated by the steroid, 20-hydroxyecdysone. Biochem J 367, 187–193.

24 Hurst D, Rylett CM, Isaac RE & Shirras AD (2003)

The Drosophila angiotensin-converting enzyme homolo- gue ANCE is required for spermiogenesis. Dev Biol 254, 238–247.

25 Williams TA, Michaud A, Houard X, Chauvet MT,

11 Donoghue M, Hsieh F, Baronas E, Godbout K, Gosse- lin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, et al. (2000) A novel angiotensin-convert- ing enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87, E1–E9. 12 Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G & Turner AJ (2000) A human homolog of angiotensin- converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275, 33238–33243.

13 Crackower MA, Sarao R, Oudit GY, Yagil C,

Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, et al. (2002) Angiotensin- converting enzyme 2 is an essential regulator of heart function. Nature 417, 822–828.

Soubrier F & Corvol P (1996) Drosophila melanogaster angiotensin I-converting enzyme expressed in Pichia pas- toris resembles the C domain of the mammalian homo- logue and does not require glycosylation for secretion and enzymic activity. Biochem J 318, 125–131.

14 Turner AJ & Hooper NM (2004) Angiotensin-convert-

26 Natesh R, Schwager SL, Evans HR, Sturrock ED &

ing enzyme 2. Handbook of Proteolytic Enzymes (Barrett, AJ, Rawlings, ND & Woessner, JF, eds), pp. 349–352. Elsevier ⁄ Academic Press, Amsterdam. 15 Guy JL, Jackson RM, Acharya KR, Sturrock ED,

Acharya KR (2004) Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry 43, 8718–8724.

27 Natesh R, Schwager SL, Sturrock ED & Acharya KR (2003) Crystal structure of the human angiotensin-con- verting enzyme-lisinopril complex. Nature 421, 551–554.

28 Kim HM, Shin DR, Yoo OJ, Lee H & Lee JO (2003)

Hooper NM & Turner AJ (2003) Angiotensin-convert- ing enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride depen- dence. Biochemistry 42, 13185–13192.

Crystal structure of Drosophila angiotensin I-converting enzyme bound to captopril and lisinopril. FEBS Lett 538, 65–70.

16 Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, et al. (2002) Hydrolysis of biological pep- tides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277, 14838–14843. 17 Coates D, Isaac RE, Cotton J, Siviter R, Williams TA,

29 Towler P, Staker B, Prasad SG, Menon S, Tang J, Par- sons T, Ryan D, Fisher M, Williams D, Dales NA, Patane MA & Pantoliano MW (2004) ACE2 x-ray structures reveal a large hinge-bending motion impor- tant for inhibitor binding and catalysis. J Biol Chem 279, 17996–18007.

Shirras A, Corvol P & Dive V (2000) Functional conser- vation of the active sites of human and Drosophila angio- tensin I-converting enzyme. Biochemistry 39, 8963–8969. 18 Burnham S, Smith JA, Lee AJ, Isaac RE & Shirras AD (2005) The angiotensin-converting enzyme (ACE) gene family of Anopheles gambiae. BMC Genomics in press.

19 Cornell MJ, Williams TA, Lamango NS, Coates D,

30 Wickham L & Desgroseillers L (1991) A bradykinin-like neuropeptide precursor gene is expressed in neuron l5 of Aplysia californica. DNA Cell Biol 10, 249–258. 31 Georgiadis D, Cuniasse P, Cotton J, Yiotakis A &

Dive V (2004) Structural determinants of rxpa380, a potent and highly selective inhibitor of the angioten- sin-converting enzyme C-domain. Biochemistry 43, 8048–8054.

Corvol P, Soubrier F, Hoheisel J, Lehrach H & Isaac RE (1995) Cloning and expression of an evolutionary conserved single-domain angiotensin converting enzyme from Drosophila melanogaster. J Biol Chem 270, 13613– 13619.

32 Liu X, Fernandez M, Wouters MA, Heyberger S &

Husain A (2001) Arg (1098) is critical for the chloride dependence of human angiotensin I-converting enzyme C-domain catalytic activity. J Biol Chem 276, 33518– 33525.

33 Naqvi N, Liu K, Graham RM & Husain A (2005)

Molecular basis of exopeptidase activity in the C-term-

20 Houard X, Williams TA, Michaud A, Dani P, Isaac RE, Shirras AD, Coates D & Corvol P (1998) The Drosophila melanogaster-related angiotensin-I-converting enzymes ACER and ANCE: distinct enzymic character- istics and alternative expression during pupal develop- ment. Eur J Biochem 257, 599–606.

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

372

R. J. Bingham et al. Structure-activity of Drosophila ACEs

inal domain of human angiotensin I-converting enzyme: Insights into the origins of its exopeptidase activity. J Biol Chem 280, 6669–6675.

formational study of a flexible peptide in dimethyl sulf- oxide by NMR and ensemble calculations. Biopolymers 40, 561–569.

36 Lamango NS & Isaac RE (1994) Identification and properties of a peptidyl dipeptidase in the housefly, Musca domestica, that resembles mammalian angioten- sin-converting enzyme. Biochem J 299, 651–657. 37 Schwede T, Kopp J, Guex N & Peitsch MC (2003)

34 Riviere G, Michaud A, Deloffre L, Vandenbulcke F, Levoye A, Breton C, Corvol P, Salzet M & Vieau D (2004) Characterization of the first non-insect inverte- brate functional angiotensin-converting enzyme (ACE): Leech TtACE resembles the N-domain of mammalian ACE. Biochem J 382, 565–573.

Swiss-model: an automated protein homology-modeling server. Nucleic Acids Res 31, 3381–3385.

35 Pellegrini M, Gobbo M, Rocchi R, Peggion E, Mammi S & Mierke DF (1996) Threonine (6)-bradykinin: con-

FEBS Journal 273 (2006) 362–373 ª 2005 The Authors Journal compilation ª 2005 FEBS

373

R. J. Bingham et al. Structure-activity of Drosophila ACEs